文献速递淋巴瘤

双难治性与双暴露性慢性淋巴细胞白血病患者的特征与结局

Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2025-01-01

分析95例慢性淋巴细胞白血病(CLL)患者在接受布鲁顿酪氨酸激酶抑制剂(BTKi)和B细胞淋巴瘤2抑制剂(BCL2i)治疗失败后的特征与结局,定义双难治(DR)为治疗期间进展、双暴露(DE)为非进展原因停药。DR组31.6%,DE组63.2%;DR组中位总生存期2.2年,DE组中位总生存期未达到。

要点

  • 双难治CLL定义为BTKi和BCL2i治疗期间出现疾病进展,双暴露为非进展原因停药。
  • 双难治组免疫球蛋白重链可变区未突变、TP53异常和BTK突变频率高于双暴露组。
  • 双难治组中位总生存期2.2年,双暴露组生存良好且后续治疗缓解持久。

核心结论

  • 双难治CLL患者生存期较短,中位总生存期2.2年,尽管对非共价BTKi或细胞治疗常见初始缓解;双暴露CLL患者生存良好,中位总生存期未达到。

研究设计与样本

  • 分析了95例接受BTKi和BCL2i治疗后失败的CLL患者的特征和结局。

主要发现

  • 双难治组30例(31.6%),双暴露组65例(63.2%)。
  • 双难治组免疫球蛋白重链可变区未突变97%、TP53异常73%、BTK突变59%,双暴露组分别为75%、46%、27%。
  • 双难治组中位总治疗线数为6,双暴露组为3。
  • 双难治组97%患者需要后续治疗,最常用非共价BTKi(34%),其次为共价BTKi联合BCL2i(28%)和CD19 CAR-T细胞(24%);双暴露组接受后续治疗较少(26%)。
  • 双难治组中位总生存期2.2年;双暴露组中位总生存期未达到,对后续治疗缓解持久。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (CLL) after Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i) failure. To clearly distinguish sensitivity and resistance to the targeted treatment classes, we defined double refractory (DR) CLL when progressive disease occurred during active treatment with a BTKi and a BCL2i, given sequentially or in combination, and double exposed (DE) disease when treatment with either or both of these agents was discontinued due to reasons other than progression. Thirty patients (31.6%) had DR CLL, and 65 (63.2%) had DE CLL. The DR group more frequently had unmutated immunoglobulin gene heavy chain variable (97%), TP53 aberration (73%), and BTK mutations (59%) than the DE group (75%, 46%, and 27%, respectively). The median number of total lines of therapy was 6 for DR and 3 for DE. Nearly all DR patients (97%) required subsequent therapy after developing DR CLL. The most commonly used treatment was noncovalent BTKis (34%), followed by concurrent covalent BTKi and BCL2i (28%) and CD19 chimeric antigen receptor-modified T cells (24%). Treatment for DE CLL was less frequently observed (26%). The median overall survival (OS) was 2.2 years once DR developed, despite the frequent initial responses to noncovalent BTKis or cellular therapy in the cohort. Patients with DE CLL demonstrated favorable survival (median OS not reached) and durable response to subsequent therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yoon JT, Zhou Y, Mikhaleva M, et al. Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia. Blood Adv. 2025. PMID: 40179394. doi:10.1182/bloodadvances.2025016006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。